Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy
Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy
复制标题
DOI：
10.1159/000494760
复制
发表时间：
2019-01-01
影响因子：
4.1
通讯作者：
Grossman, Ashley
中科院分区：
文献类型：
--
作者：
Navalkissoor, Shaunak;Grossman, Ashley
神经内分泌肿瘤（NETs）越来越常见，但迄今为止只有完全手术切除是治愈的。然而，在各种治疗选择中，肽受体放射性核素治疗，将放射性片段与奥曲肽衍生物连接，已被证明是一种高效且耐受性良好的治疗方法，可改善无进展生存期和可能的总生存期。然而，目前使用的放射性核素是具有非最佳放射生物学特性的β粒子发射器。新一代发射α粒子的放射性核素正在研制中，其优点是能量非常高，路径长度很短，理论上应该具有更高的功效。我们调查了这一领域的当前发展，强调了这种新形式的NETs治疗的令人兴奋的潜力。(C) 2018年代。巴塞尔的大公司
Neuroendocrine tumours (NETs) are being seen increasingly frequently, but to date only complete surgical resection is curative. However, among the various therapeutic options, peptide receptor radionuclide therapy, linking a radioactive moiety to an octreotide derivative, has been shown to be highly efficacious and a well-tolerated therapy, improving progression-free survival and probably overall survival. Nevertheless, the current radionuclides in use are beta particle emitters with non-optimal radiobiological properties. A new generation of alpha particle-emitting radionuclides is being developed, with advantages in terms of very high energy and a short path length, which should theoretically show higher efficacy. We survey the current developments in this field, emphasising the exciting potential of this novel form of therapy for NETs. (C) 2018S. Karger AG, Basel